Document Detail


Matrix metalloproteinases: a potential therapeutic target in atherosclerosis.
MedLine Citation:
PMID:  16503874     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
Mature human atherosclerotic plaques are frequently characterized by a lipid-rich core covered by a fibrous cap composed of fibrillar collagens, elastin, proteoglycans and smooth muscle cells (SMC). Most sudden deaths due to acute myocardial infarction are caused by rupture of coronary atheroma, leading to a prothrombotic response followed by rapid occlusion of the artery. The accumulation of macrophage-derived foam cells in vulnerable shoulder regions of atherosclerotic plaques correlates with increased local release of matrix-degrading metalloproteinases (MMPs) and weak fibrous cap tissue. These findings suggest a potential role of macrophage-derived MMPs in the weakening and ultimate rupture of plaque structures. Consequently, several studies have focussed on the hypothesis that inhibiting MMP activity would reduce plaque volume and prevent plaque rupture and therefore would be useful in the treatment of atherosclerosis. However, current synthetic MMP inhibitors are not very specific and clinical results have so far been inconclusive. The development of selective inhibitors and focal gene transfer approaches may be better suited for the treatment of atherosclerosis.
Authors:
Mustapha Rouis
Related Documents :
619594 - Relationship between myocardial infarction and preinfarction angina: a histopathologica...
20559964 - Vulnerable plaque imaging-current techniques.
11213734 - Two cases of orbital infarction syndrome.
20106634 - Ventricular septal rupture and right ventricular free wall dissection after inferior my...
8059724 - Peripheral vascular complications of directional coronary atherectomy and stenting: pre...
9950844 - A canine model of chronic ischemic cardiomyopathy: characterization of regional flow-fu...
Publication Detail:
Type:  Journal Article; Review    
Journal Detail:
Title:  Current drug targets. Cardiovascular & haematological disorders     Volume:  5     ISSN:  1568-0061     ISO Abbreviation:  Curr Drug Targets Cardiovasc Haematol Disord     Publication Date:  2005 Dec 
Date Detail:
Created Date:  2006-02-28     Completed Date:  2006-03-31     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  101123341     Medline TA:  Curr Drug Targets Cardiovasc Haematol Disord     Country:  Netherlands    
Other Details:
Languages:  eng     Pagination:  541-8     Citation Subset:  IM    
Affiliation:
Institut National de la Santé et de la Recherche Médicale (INSERM) U-545, Nuclear receptors, lipoproteins and atherosclerosis, Institut Pasteur de Lille, France. Mustapha.Rouis@pasteur-lille.fr
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Animals
Atherosclerosis / drug therapy*,  enzymology
Humans
Matrix Metalloproteinases / antagonists & inhibitors,  metabolism*
Models, Biological
Tissue Inhibitor of Metalloproteinases / therapeutic use*
Chemical
Reg. No./Substance:
0/Tissue Inhibitor of Metalloproteinases; EC 3.4.24.-/Matrix Metalloproteinases

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Liver x receptors: potential novel targets in cardiovascular diseases.
Next Document:  Endocannabinoid receptor antagonists and other emerging pharma-cological strategies for weight reduc...